Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003548 · ClinicalTrials.gov registry record · Phase 1
Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity
A Phase 1 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00003548 is a Phase 1 study that has completed, run by NYU Langone Health. The registered enrollment target is 20 participants.
The verdict
NCT00003548, a Phase 1 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced cancer of the peritoneal cavity.
Interventions
- DRUG aminocamptothecin colloidal dispersion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 1998-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003548
The ClinicalTrials.gov registry entry for NCT00003548 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which aminocamptothecin colloidal dispersion is the first listed.
NCT00003548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003548 about?
NCT00003548 is a clinical study titled "Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal Cavity". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of aminocamptothecin in treating patients with advanced cancer of the peritoneal cavity.
What is the current status of trial NCT00003548?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 1998-08.
What interventions are being tested in trial NCT00003548?
The interventions under investigation include: aminocamptothecin colloidal dispersion (DRUG).
Who is sponsoring clinical trial NCT00003548?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.